FDA: PPIs and Clostridium Difficile

Published Online: Friday, July 20, 2012
Follow Pharmacy_Times:
In this podcast, Steve Jackson, a pharmacist in the FDA’s division of drug information, warns that use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea.
 
To listen to the podcast, click here.
Related Articles
As nearly one-third of patients with gastroesophageal reflux disease are partial responders to proton pump inhibitors (PPIs), health care professionals could benefit from reliable methods that predict who will respond to PPIs and who will not.
The My GI Health tool tracks symptoms of gastroesophageal reflux disease over time, helping clinicians save time and improve patient care.
Community pharmacists need to expand their comfort zones regarding chemotherapy.
Latest Issues
$auto_registration$